Prenetics Global Ltd
PRE Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Prenetics Global Ltd had $92.4M of revenue in fiscal 2025, up 479.8% on the year before. Over five years, revenue changed +7.2% a year on average.
- Its operating margin was −48.1%, up 179.5 pts: of every 100 in sales, about −48 is left after running the business.
- Prenetics Global Ltd lost $37.7M in fiscal 2025.
- Free cash flow was −$22.0M in fiscal 2025, −23.8% of revenue.
Market cap
—
P/E
—
Revenue
$92.4M
Net income
−$37.7M
Free cash flow
−$22.0M
Operating margin
−48.1%
Prenetics Global Ltd in 30 seconds · fiscal 2025
Are sales growing?
+479.8%
Yes. Sales grew 479.8% last year.
Does it make a profit?
−40.8%
No. It lost money last year.
Does profit turn into cash?
−23.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
What Prenetics Global Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 30, 2026
- Legal name
- Prenetics Global Ltd
- CIK
- 0001876431
Prenetics Global Ltd · PRE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $12.5M | $13.2M | $21.7M | $15.9M | $92.4M |
| Revenue growth | −80.8% | 5.0% | 65.2% | −26.7% | 479.8% |
| Gross margin | 28.7% | 27.5% | 5.4% | 58.2% | 52.8% |
| Operating margin | −452.1% | −501.5% | −176.8% | −227.6% | −48.1% |
| Net income | −$174M | −$190M | −$62.7M | −$46.3M | −$37.7M |
| Net margin | −1,388.4% | −1,446.8% | −288.5% | −290.6% | −40.8% |
| Diluted EPS | −$178.81 | −$37.57 | −$5.58 | −$3.71 | −$2.68 |
| Cash | |||||
| Cash from operations | $13.4M | $14.5M | −$13.8M | −$28.9M | −$21.8M |
| Capital expenditure | $8.5M | $4.9M | $0.3M | $1.0M | $0.2M |
| Free cash flow | $4.9M | $9.6M | −$14.1M | −$29.9M | −$22.0M |
| FCF margin | 38.9% | 72.7% | −64.9% | −187.5% | −23.8% |
| Share count change | −92.6% | 420.9% | 121.8% | 11.1% | 12.5% |
| Debt and strength | |||||
| Cash and short-term investments | $35.3M | $147M | $45.7M | $52.3M | $32.1M |
| Shareholders' equity | −$401M | $237M | $206M | $170M | $156M |
| Current ratio | 1.8x | 4.2x | 2.4x | 2.4x | 3.0x |
| Interest coverage | −10.8x | −15.7x | — | — | — |
| Returns and quality | |||||
| Return on equity | — | — | −28.3% | −24.6% | −23.1% |
| Return on tangible equity | — | −101.0% | −38.3% | −38.1% | −24.3% |
| Piotroski F-score | — | 4 | 3 | 3 | 4 |
Insiders bought, 12 months
$1.0M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Prenetics Global Ltd · PRE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001876431). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.